220 related articles for article (PubMed ID: 37987124)
1. [Related factors of viral nucleic acid change in critically ill patients with SARS-CoV-2 infection after treatment with Nirmatrelvir/Ritonavir: a single center retrospective cohort study].
Yan M; Xie M; Zhu S; Li H; Li S
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Nov; 35(11):1150-1156. PubMed ID: 37987124
[TBL] [Abstract][Full Text] [Related]
2. Persistent lymphocyte reduction and interleukin-6 levels are independently associated with death in patients with COVID-19.
Xu Y; Wang N; Shen X; Liu X; Liu H; Liu Y
Clin Exp Med; 2023 Nov; 23(7):3719-3728. PubMed ID: 37310657
[TBL] [Abstract][Full Text] [Related]
3. Association of Nirmatrelvir/Ritonavir Treatment on Upper Respiratory Severe Acute Respiratory Syndrome Coronavirus 2 Reverse Transcription-Polymerase Chain Reaction (SARS-Cov-2 RT-PCR) Negative Conversion Rates Among High-Risk Patients With Coronavirus Disease 2019 (COVID-19).
Li H; Gao M; You H; Zhang P; Pan Y; Li N; Qin L; Wang H; Li D; Li Y; Qiao H; Gu L; Xu S; Guo W; Wang N; Liu C; Gao P; Niu J; Cao J; Zheng Y
Clin Infect Dis; 2023 Feb; 76(3):e148-e154. PubMed ID: 35870128
[TBL] [Abstract][Full Text] [Related]
4. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants.
Wang Y; Zhao D; Chen X; Liu X; Xiao W; Feng L
Influenza Other Respir Viruses; 2023 Feb; 17(2):e13095. PubMed ID: 36843224
[TBL] [Abstract][Full Text] [Related]
5. COVID-19 Rebound After VV116 vs Nirmatrelvir-Ritonavir Treatment: A Randomized Clinical Trial.
Yang Z; Xu Y; Zheng R; Ye L; Lv G; Cao Z; Han R; Li M; Zhu Y; Cao Q; Ding Y; Wang J; Tan Y; Liu F; Wei D; Tan W; Jiang W; Sun J; Sun S; Shao J; Deng Y; Gao W; Wang W; Zhao R; Qiu L; Chen E; Zhang X; Wang S; Ning G; Xu Y; Bi Y
JAMA Netw Open; 2024 Mar; 7(3):e241765. PubMed ID: 38477921
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet Infect Dis; 2022 Dec; 22(12):1681-1693. PubMed ID: 36029795
[TBL] [Abstract][Full Text] [Related]
7. Clinical, Virologic, and Immunologic Evaluation of Symptomatic Coronavirus Disease 2019 Rebound Following Nirmatrelvir/Ritonavir Treatment.
Epling BP; Rocco JM; Boswell KL; Laidlaw E; Galindo F; Kellogg A; Das S; Roder A; Ghedin E; Kreitman A; Dewar RL; Kelly SEM; Kalish H; Rehman T; Highbarger J; Rupert A; Kocher G; Holbrook MR; Lisco A; Manion M; Koup RA; Sereti I
Clin Infect Dis; 2023 Feb; 76(4):573-581. PubMed ID: 36200701
[TBL] [Abstract][Full Text] [Related]
8. Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study.
Wong CKH; Lau KTK; Au ICH; Lau EHY; Poon LLM; Hung IFN; Cowling BJ; Leung GM
Lancet Infect Dis; 2023 Jun; 23(6):683-695. PubMed ID: 36796397
[TBL] [Abstract][Full Text] [Related]
9. Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent Long COVID symptoms in an observational cohort study.
Durstenfeld MS; Peluso MJ; Lin F; Peyser ND; Isasi C; Carton TW; Henrich TJ; Deeks SG; Olgin JE; Pletcher MJ; Beatty AL; Marcus GM; Hsue PY
J Med Virol; 2024 Jan; 96(1):e29333. PubMed ID: 38175151
[TBL] [Abstract][Full Text] [Related]
10. Real-world effectiveness of molnupiravir and nirmatrelvir plus ritonavir against mortality, hospitalisation, and in-hospital outcomes among community-dwelling, ambulatory patients with confirmed SARS-CoV-2 infection during the omicron wave in Hong Kong: an observational study.
Wong CKH; Au ICH; Lau KTK; Lau EHY; Cowling BJ; Leung GM
Lancet; 2022 Oct; 400(10359):1213-1222. PubMed ID: 36216007
[TBL] [Abstract][Full Text] [Related]
11. [Clinical features and risk factors for secondary hemophagocytic lymphohistiocytosis in elderly patients with severe SARS-CoV-2 infection: a multicenter retrospective cohort study].
Deng Y; Lu S; Zhang G; Sun W; Chu Y; Meng M; Cui Y; Li P
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2023 Aug; 35(8):793-799. PubMed ID: 37593855
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022.
Harrington PR; Cong J; Troy SB; Rawson JMO; O'Rear JJ; Valappil TI; McGarry Connelly S; Farley J; Birnkrant D
MMWR Morb Mortal Wkly Rep; 2023 Dec; 72(51):1365-1370. PubMed ID: 38127674
[TBL] [Abstract][Full Text] [Related]
13. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
Aggarwal NR; Molina KC; Beaty LE; Bennett TD; Carlson NE; Mayer DA; Peers JL; Russell S; Wynia MK; Ginde AA
Lancet Infect Dis; 2023 Jun; 23(6):696-705. PubMed ID: 36780912
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
15. Nirmatrelvir-ritonavir therapy and COVID-19 vaccination improve clinical outcomes of SARS-CoV-2 Omicron variant infection.
Qi T; Jin Y; Wang H; Liao Y; Liu T; Mao E; Li F; Li Y; Fan X; Ling Y
J Med Virol; 2023 Feb; 95(2):e28497. PubMed ID: 36651302
[TBL] [Abstract][Full Text] [Related]
16. Analysis of All-Cause Hospitalization and Death Among Nonhospitalized Patients With Type 2 Diabetes and SARS-CoV-2 Infection Treated With Molnupiravir or Nirmatrelvir-Ritonavir During the Omicron Wave in Hong Kong.
Lui DTW; Chung MSH; Lau EHY; Lau KTK; Au ICH; Lee CH; Woo YC; Wong CKH; Cowling BJ
JAMA Netw Open; 2023 May; 6(5):e2314393. PubMed ID: 37204790
[TBL] [Abstract][Full Text] [Related]
17. Obesity May Not Be Associated with 28-Day Mortality, Duration of Invasive Mechanical Ventilation and Length of Intensive Care Unit and Hospital Stay in Critically Ill Patients with Severe Acute Respiratory Syndrome Coronavirus-2: A Retrospective Cohort Study.
Pouwels S; Ramnarain D; Aupers E; Rutjes-Weurding L; van Oers J
Medicina (Kaunas); 2021 Jun; 57(7):. PubMed ID: 34210077
[No Abstract] [Full Text] [Related]
18. Remdesivir or Nirmatrelvir/Ritonavir Therapy for Omicron SARS-CoV-2 Infection in Hematological Patients and Cell Therapy Recipients.
Piñana JL; Heras I; Aiello TF; García-Cadenas I; Vazquez L; Lopez-Jimenez J; Chorão P; Aroca C; García-Vidal C; Arroyo I; Soler-Espejo E; López-Corral L; Avendaño-Pita A; Arrufat A; Garcia-Gutierrez V; Arellano E; Hernández-Medina L; González-Santillana C; Morell J; Hernández-Rivas JÁ; Rodriguez-Galvez P; Mico-Cerdá M; Guerreiro M; Campos D; Navarro D; Cedillo Á; Martino R; Solano C;
Viruses; 2023 Oct; 15(10):. PubMed ID: 37896843
[TBL] [Abstract][Full Text] [Related]
19. [Correlation between the early dynamic changes of lymphocyte and severity of disease in coronavirus disease 2019 patients].
Zhou J; Zhou Y; Cai J; Lin S
Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2021 Aug; 33(8):922-926. PubMed ID: 34590557
[TBL] [Abstract][Full Text] [Related]
20. Real-world effectiveness of molnupiravir, nirmatrelvir-ritonavir, and sotrovimab on preventing hospital admission among higher-risk patients with COVID-19 in Wales: A retrospective cohort study.
Evans A; Qi C; Adebayo JO; Underwood J; Coulson J; Bailey R; Lyons R; Edwards A; Cooper A; John G; Akbari A
J Infect; 2023 Apr; 86(4):352-360. PubMed ID: 36773891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
